Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Expert Insight on Key Data From WCLC 2020 in Early-Stage Lung Cancer

January 28-31, 2021; Virtual Meeting
In this podcast episode, listen to Jamie E. Chaft, MD, discuss her thoughts on new data and studies focused on early-stage NSCLC presented at WCLC 2020.
Jamie E. Chaft, MD
Released: February 24, 2021

In this episode, Jamie E. Chaft, MD, provides her expert perspective on new data from WCLC 2020 in early-stage NSCLC, with topics including:

  • Updated results from ADAURA on HRQoL and DFS outcomes with or without postoperative chemotherapy after adjuvant osimertinib
  • An analysis of the ongoing ITACA study of personalizing chemotherapy based on biomarkers of drug resistance
  • FDG PET/CT adaptive radiotherapy in RTOG 1106
  • The TALENT study in Taiwan screening nonsmokers for lung cancer

Presenter:

Jamie E. Chaft, MD
Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
Bristol-Myers Squibb
Ipsen Biopharmaceuticals, Inc.
Janssen Pharmaceutica NV
Jazz Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme
Takeda Oncology

Related Content

Update of ATEZO-BRAIN trial evaluating atezolizumab plus chemotherapy in patients with advanced nonsquamous NSCLC with untreated brain metastases, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 16, 2022

Phase I CHRYSALIS-2 updates: amivantamab + lazertinib in EGFRm NSCLC after progression with osimertinib and chemotherapy, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 14, 2022

Adagrasib shows early encouraging activity in patients with KRAS G12C-mutant NSCLC and active, untreated CNS metastases, from Clinical Care Options (CCO) coverage of ASCO 2022

Released: June 13, 2022

Phase II NADIM II trial evaluating neoadjuvant nivolumab plus chemotherapy for resectable stage IIIA/B NSCLC, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 10, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings